Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Silent ischaemia in familial hypercholesterolemia

Olivier S Descamps, Antoine de Meester, Paul Cheron

    Atherosclerosis. Supplements
    |November 15, 2003
    PubMed

    Insights

    Familial hypercholesterolemia (FH) men aged 25-55 show high rates of coronary heart disease (52%), including asymptomatic myocardial ischemia. Early exercise testing is crucial for detecting severe coronary artery disease in these individuals.

    Area of Science:

    • Cardiology
    • Genetics
    • Preventive Medicine

    Background:

    • Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol and premature cardiovascular disease.
    • Early detection and management of coronary heart disease (CHD) in FH patients are critical for preventing adverse outcomes.

    Discussion:

    • A significant proportion of FH men aged 25-55 exhibit signs of coronary heart disease, including symptomatic and asymptomatic myocardial ischemia.
    • Asymptomatic myocardial ischemia in FH men is frequently associated with severe coronary artery stenosis, necessitating intervention.
    • Exercise stress testing identified significant ST/T changes in 20% of FH men, with 75% of those undergoing angiography showing severe disease.

    Key Insights:

    • The incidence of coronary heart disease in this FH cohort was 52%, with 32% having a history of symptomatic disease.
    • Even silent myocardial ischemia in FH men is linked to severe coronary artery disease, requiring prompt attention.
    • Coronary angioplasty or bypass surgery was performed on 4 out of 6 patients with severe stenosis identified via exercise stress testing.

    Outlook:

    • Systematic exercise testing should be implemented for all asymptomatic FH men over the age of 25.
    • Further research should explore long-term outcomes and optimal screening strategies for FH populations.
    • Integrating genetic screening with cardiovascular risk assessment can improve early diagnosis and treatment of FH.

    More Related Videos

    A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

    A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

    Published on: September 15, 2018

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    Related Concept Videos

    Inflammation01:38

    Inflammation

    Overview
    Ischemic Heart Disease: Overview01:17

    Ischemic Heart Disease: Overview

    Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
    Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Atherosclerosis I: Introduction01:30

    Atherosclerosis I: Introduction

    Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

    Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

    Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...